These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 31877318

  • 1. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma.
    Barceló C, Sisó P, Maiques O, García-Mulero S, Sanz-Pamplona R, Navaridas R, Megino C, Felip I, Urdanibia I, Eritja N, Soria X, Piulats JM, Penin RM, Dolcet X, Matías-Guiu X, Martí RM, Macià A.
    J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
    [Abstract] [Full Text] [Related]

  • 2. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma.
    Kim YJ, Tsang T, Anderson GR, Posimo JM, Brady DC.
    Cancer Res; 2020 Apr 01; 80(7):1387-1400. PubMed ID: 32005716
    [Abstract] [Full Text] [Related]

  • 4. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.
    Mol Cancer Ther; 2014 Feb 01; 13(2):353-63. PubMed ID: 24398428
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
    Ma ZR, Xiong QW, Cai SZ, Ding LT, Yin CH, Xia HL, Liu W, Dai S, Zhang Y, Zhu ZH, Huang ZJ, Wang Q, Yan XM.
    Int Immunopharmacol; 2023 Sep 01; 122():110617. PubMed ID: 37478666
    [Abstract] [Full Text] [Related]

  • 8. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
    Brummer C, Faerber S, Bruss C, Blank C, Lacroix R, Haferkamp S, Herr W, Kreutz M, Renner K.
    Cancer Lett; 2019 Feb 01; 442():453-463. PubMed ID: 30481565
    [Abstract] [Full Text] [Related]

  • 9. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
    Carroll MJ, Parent CR, Page D, Kreeger PK.
    BMC Cancer; 2019 Oct 31; 19(1):1025. PubMed ID: 31672130
    [Abstract] [Full Text] [Related]

  • 10. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAFV600E inhibitor-resistant metastatic melanoma cells.
    Martin S, Dudek-Peric AM, Garg AD, Roose H, Demirsoy S, Van Eygen S, Mertens F, Vangheluwe P, Vankelecom H, Agostinis P.
    Autophagy; 2017 Sep 02; 13(9):1512-1527. PubMed ID: 28722539
    [Abstract] [Full Text] [Related]

  • 11. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.
    Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield KM, Chen S, Pine S, Jeyamohan C, Sokol L, Ali S, Teo ML, White E, Rodriguez-Rodriguez L, Mehnert JM, Ganesan S.
    Clin Cancer Res; 2017 Sep 15; 23(18):5631-5638. PubMed ID: 28539463
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E.
    Chang X, Zhang T, Wang Q, Rathore MG, Reddy K, Chen H, Shin SH, Ma WY, Bode AM, Dong Z.
    Theranostics; 2020 Sep 15; 10(21):9721-9740. PubMed ID: 32863956
    [Abstract] [Full Text] [Related]

  • 15. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAFV600E mutation bearing metastatic melanoma cells.
    Carpenter EL, Chagani S, Nelson D, Cassidy PB, Laws M, Ganguli-Indra G, Indra AK.
    Mol Carcinog; 2019 Sep 15; 58(9):1680-1690. PubMed ID: 31211467
    [Abstract] [Full Text] [Related]

  • 16. The Evolution of Acquired Resistance to BRAFV600E kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling.
    Xu G, Luo Y, Wu W, Liu X, Yu X, Bao Y, He X, Yu J, Li Y, Yang J, Zhang R, Yu C, Chen H, Xu J, Hu J, Jing J, Shi H.
    J Invest Dermatol; 2022 Feb 15; 142(2):445-458. PubMed ID: 34358527
    [Abstract] [Full Text] [Related]

  • 17. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
    Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J.
    PLoS One; 2013 Feb 15; 8(8):e72692. PubMed ID: 24023633
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
    Uebel A, Kewitz-Hempel S, Willscher E, Gebhardt K, Sunderkötter C, Gerloff D.
    Int J Mol Sci; 2023 Jan 19; 24(3):. PubMed ID: 36768289
    [Abstract] [Full Text] [Related]

  • 20. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
    Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.
    Oncotarget; 2016 Dec 13; 7(50):81995-82012. PubMed ID: 27835901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.